ArticleCell reports. Medicine2021
Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Article
- The role of integrins in T cell-mediated resistance tobioRxiv : the preprint server for biology · 2026Article
- A single-cell atlas of ulcerative colitis reveals neutrophil-stromal circuits linked to biologic therapy resistance.Frontiers in immunology · 2026Article
- Integrin α4β7: Pathogenic Roles in Metabolic and Inflammatory Diseases and Translational Therapeutics.Journal of inflammation research · 2026Review
- Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers.Small methods · 2026Review
- Intestinal tissue-resident memory T cells: Characteristics, spatial heterogeneity, age-related dynamics, and roles in disease regulation.Journal of advanced research · 2026Review
- The interaction between dendritic cells and T follicular helper cells drives inflammatory bowel disease: a review.Frontiers in immunology · 2026Review
- Gut microbiota and ankylosing spondylitis: mechanisms, functional pathways, and research trends.Frontiers in microbiology · 2026Article
- Research progress in molecular targeted therapy for inflammatory bowel disease.Journal of translational medicine · 2025Review
- A Charge-Adhesive Targeted DNA Gel Bandage for the Precision Treatment of Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Molecular exaptation by the integrin αI domain.Science advances · 2025Article
- MAIT cell homing in intestinal homeostasis and inflammation.Science advances · 2025Review
- Gut microbiota and ankylosing spondylitis: current insights and future challenges.Microbial cell (Graz, Austria) · 2025Review
- Acetyl-NPKY of integrin-β1 binds KINDLIN2 to control endothelial cell proliferation and junctional integrity.iScience · 2024Article
- Meningeal lymphatic CGRP signaling governs pain via cerebrospinal fluid efflux and neuroinflammation in migraine models.The Journal of clinical investigation · 2024Article
- Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.Nature biomedical engineering · 2024Article
- Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells.Nature communications · 2024Article
- Vagal innervation limits brain injury by inhibiting gut-selective integrin-mediated intestinal immunocyte migration in intracerebral hemorrhage.Theranostics · 2024Article
- Meta-analysis of etrolizumabTherapeutic advances in gastroenterology · 2024Article
- Lymphocyte migration regulation related proteins in urine exosomes may serve as a potential biomarker for lung cancer diagnosis.BMC cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-integrins are therapeutically effective for inflammatory bowel disease, yet the relative contribution of α4β7 and αEβ7 to gut lymphocyte trafficking is not fully elucidated. Here, we evaluate the effect of α4β7 and αEβ7 blockade using a combination of murine models of gut trafficking and longitudinal gene expression analysis in etrolizumab-treated patients with Crohn's disease (CD). Dual blockade of α4β7 and αEβ7 reduces CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.